Bokf Na Sells 8,455 Shares of IQVIA Holdings Inc. $IQV

Bokf Na decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 69.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,770 shares of the medical research company’s stock after selling 8,455 shares during the period. Bokf Na’s holdings in IQVIA were worth $850,000 at the end of the most recent reporting period.

Several other hedge funds also recently modified their holdings of the company. Acorn Financial Advisory Services Inc. ADV acquired a new stake in shares of IQVIA during the fourth quarter worth approximately $241,000. Principal Financial Group Inc. increased its holdings in shares of IQVIA by 2.6% during the fourth quarter. Principal Financial Group Inc. now owns 189,301 shares of the medical research company’s stock worth $42,670,000 after buying an additional 4,862 shares in the last quarter. QRG Capital Management Inc. increased its holdings in shares of IQVIA by 21.8% during the fourth quarter. QRG Capital Management Inc. now owns 4,494 shares of the medical research company’s stock worth $1,013,000 after buying an additional 804 shares in the last quarter. Pinnacle Wealth Management Advisory Group LLC acquired a new stake in shares of IQVIA during the fourth quarter worth approximately $412,000. Finally, Riverstone Advisors LLC acquired a new stake in shares of IQVIA during the fourth quarter worth approximately $276,000. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Price Performance

IQV opened at $178.48 on Friday. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $247.04. The company has a debt-to-equity ratio of 2.20, a current ratio of 0.75 and a quick ratio of 0.75. The company’s 50 day simple moving average is $170.14 and its 200-day simple moving average is $200.95. The stock has a market capitalization of $29.79 billion, a P/E ratio of 22.12, a price-to-earnings-growth ratio of 1.72 and a beta of 1.18.

IQVIA (NYSE:IQV) last released its quarterly earnings results on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The business had revenue of $4.15 billion for the quarter, compared to analysts’ expectations of $4.10 billion. During the same period in the prior year, the firm earned $2.70 earnings per share. IQVIA’s revenue was up 8.4% compared to the same quarter last year. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Sell-side analysts anticipate that IQVIA Holdings Inc. will post 11.5 earnings per share for the current fiscal year.

IQVIA announced that its board has approved a stock buyback plan on Thursday, May 7th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to repurchase up to 6.8% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on the stock. UBS Group dropped their price objective on shares of IQVIA from $280.00 to $240.00 and set a “buy” rating for the company in a report on Friday, February 6th. Mizuho set a $215.00 price objective on shares of IQVIA in a report on Monday, February 23rd. Evercore reaffirmed an “outperform” rating and set a $185.00 price objective on shares of IQVIA in a report on Wednesday, April 8th. JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating for the company in a report on Friday, February 6th. Finally, TD Cowen raised shares of IQVIA from a “hold” rating to a “buy” rating and raised their price objective for the stock from $174.00 to $213.00 in a report on Monday, March 9th. Two equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $225.69.

IQVIA Company Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.